This report outlays comprehensive insights of present scenario and growth prospects across Severe Psoriasis. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
Products covered by Phase
Phase III, Phase II, Phase I
Pre-clinical & Discovery
Inactive (Discontinued and Dormant)
Overview of pipeline development activities for Severe Psoriasis
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Severe Psoriasis
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication
Companies Mentioned
Almirall
AstraZeneca Plc
Boehringer Ingelheim GmbH
Celgene Corporation
Eli Lilly and Company
Forward Pharma A/S
Galectin Therapeutics
Idera Pharmaceuticals
Scope of the report
Provides an overview of therapeutic pipeline activity for Severe Psoriasis across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Severe Psoriasis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
Coverage of dormant and discontinued pipeline projects across Severe Psoriasis
Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Severe Psoriasis to formulate effective R&D strategies
Assess challenges and opportunities that influence Severe Psoriasis R&D
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Severe Psoriasis to enhance and expand business potential and scope
Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Key Topics Covered:
1. Report Introduction
2. Severe Psoriasis - Disease Overview
3. Pipeline Outlook
An Overview of Pipeline Products for Severe Psoriasis
4. Comparative Analysis
5. Severe Psoriasis Therapeutic Products in Clinical Stage 5.1 Drug Name : Company Name
Product Description
Research and Development
Product Development Activities
6. Severe Psoriasis Therapeutic Products in Non-clinical Stage 6.1 Drug Name : Company Name
Product Description
Research and Development
Product Development Activities
7. Therapeutic Pipeline Analysis
Pipeline Analysis by Route of Administration
Pipeline Analysis by Stage and Route of Administration
Pipeline Analysis by Molecule Type
Pipeline Analysis by Stage and Molecule Type
8. Inactive Pipeline Products 8.1 Drug Description
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed,...
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...